Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

Garvey, W. Timothy, Birkenfeld, Andreas L., Dicker, Dror, Mingrone, Geltrude, Pedersen, Sue D., Satylganova, Altynai, Skovgaard, Dorthe, Sugimoto, Danny, Jensen, Camilla, Mosenzon, Ofri·2020·Diabetes Care
DOI 10.2337/dc19-1745

Cited by (186)

Items 101–186 of 186

  1. Obesity-Related Genes Expression in Testes and Sperm Parameters Respond to GLP-1 and Caloric Restriction
    Ana S. Correia, Sara Pereira, Tiago Morais, Ana Dias Martins, Mariana Pereira Monteiro, Marco Gouveia Alves, Pedro Fontes Oliveira · 2022 · Biomedicines
  2. Individualized diabetes care: Lessons from the real-world experience
    Xiao Ying Khor, Joseph M Pappachan, Mohammad Sadiq Jeeyavudeen · 2023 · World Journal of Clinical Cases
  3. Ion channels regulate energy homeostasis and the progression of metabolic disorders: Novel mechanisms and pharmacology of their modulators
    Wenyi Wu, Jianan Zheng, Ru Wang, Yibing Wang · 2023 · Biochemical Pharmacology
  4. GLP-1 analogues in clinical management of obesity
    Rachel Agius, Cláudia Matta-Coelho, Barbara McGowan · 2022 · Current Opinion in Endocrine and Metabolic Research
  5. Aging-Related Obesity: Unveiling Mitochondrial and Metabolic Dysfunction
    Tongbing Qi, Kexin Zhang, Jingwen Zhang, Yujie Ma, Ningning Hou, Xiaodong Sun, Fang Han, Sufang Sheng, Chengxia Kan · 2025 · Current Nutrition Reports
  6. Once-Weekly Semaglutide Improves Body Composition in Spanish Obese Adults with Type 2 Diabetes: A 48-Week Prospective Real-Life Study
    Irene Caballero Mateos, Cristóbal Morales, Beatriz González Aguilera · 2025 · Journal of Clinical Medicine
  7. Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies
    Adil Farooq Wali, Imran Rashid Rangraze, Shehla Shafi Khan, Uwais Mufti, Mohamed El‐Tanani, Manfredi Rizzo · 2026 · Frontiers in Pharmacology
  8. Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool
    Eleni A. Karavia, Panagiota C. Giannopoulou, Vassiliki Konstantinopoulou, Katerina Athanasopoulou, Theodosios D. Filippatos, Demosthenes B. Panagiotakos, Kyriakos E. Kypreos · 2023 · Nutrients
  9. Liraglutide Protects Pancreatic Islet From Ischemic Injury by Reducing Oxidative Stress and Activating Akt Signaling During Cold Preservation to Improve Islet Transplantation Outcomes
    Xiangheng Cai, Jing-Lin Cao, Le Wang, Jia-Qi Zou, Rui Li, Peng Sun, Xue-Jie Ding, B. Zhang, Ze-Wen Liu, Xi-Rui Pei et al. · 2024 · Transplantation
  10. Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review
    Teodor Salmen, Claudia-Gabriela Potcovaru, Ioana-Cristina Bica, Rosaria Vincenza Giglio, Angelo Maria Patti, Roxana Adriana Stoica, Marcello Ciaccio, Mohamed El‐Tanani, Andrej Janež, Manfredi Rizzo et al. · 2024 · Pharmaceuticals
  11. Obesity and Male Infertility: True, True, and Unrelated?
    Carl A. Ceraolo, Amanda Rubano, J. Scott Gabrielsen · 2023 · Seminars in Reproductive Medicine
  12. Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects
    Kushner, Robert F., Johansen, Odd Erik, Araujo Torres, Krysmaru, Phan, Trà-Mi, Marczewska, Agnieszka · 2025 · Obesities
  13. Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review
    Nandan Joshi, Kanwal Baloch, Shah Rukh, Abdul Moiz Khan, Fnu Muskan, Verkha Kumari, Hasher Khan, Mohd Zeeshan, Ghufran Azam, Saif Khalid et al. · 2024 · Annals of Medicine and Surgery
  14. Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis
    Abraish Ali, Asad Ali Siddiqui, Muhammad Usman, Izza Shahid, Muhammad Shahzeb Khan, Prinka Perswani · 2025 · Clinical Obesity
  15. Efficacy of Liraglutide for Weight Loss in Overweight and Obese Non-diabetic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Néstor Israel Quinapanta Castro, Mishell Almeida, Andres F Orbea, Domenica N Andrade, Jonathan Flores Carrera, Francisco Yepez Vargas, Mariela L Carrasco · 2025 · Cureus
  16. Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review
    Abdullah Al Lawati, Ayman N. Alhabsi, Rhieya Rahul, Maria-Luisa Savino, Hamed Alwahaibi, Srijit Das, Hanan Al Lawati · 2025 · Diseases
  17. Pharmacologic treatment of obesity
    Han Na Jung, Chang Hee Jung · 2022 · Journal of Korean Medical Association
  18. Efficacy and safety of European Medicines Agency ( EMA )‐approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta‐analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity
    Rocco Barazzoni, Matteo Monami, Silvio Buscemi, Luca Busetto, Maurizio De Luca, Giuseppe Navarra, Benedetta Ragghianti, Giovanni Antonio Silverii, Amanda Belluzzi, Edoardo Mannucci et al. · 2025 · Diabetes Obesity and Metabolism
  19. Liraglutide for adults living with obesity
    Nicolás Meza, Javier Bracchiglione, Camila Micaela Escobar Liquitay, Eva Madrid A, Lucia B Varela, Yang Guo, Gerard Urrútia, S. F. Schaf er, S. Tiller, Kamyar Shokraee et al. · 2025 · Cochrane Database of Systematic Reviews
  20. Combining Metabolic Surgery with Medications for Type 2 Diabetes
    Alexis C. Sudlow, Dimitri J. Pournaras, Carel Wynand le Roux · 2022 · Journal of Bariatric Surgery
  21. Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates
    Dima Kamal Abdelmannan, Manal AlBuflasa, Heitham K. Ajlouni, Marwan Abdelrahim Zidan, Farya Rahman, Muhammad H. Farooqi, Augusto Enrique Caballero · 2023 · Diabetes Research and Clinical Practice
  22. Evaluating the bioequivalence and safety of liraglutide injection versus Victoza® in healthy Chinese subjects: a randomized, open, two-cycle, self-crossover phase I clinical trial
    Chao Liu, Hongrong Xu, Fei Yuan, Hanjing Chen, Lei Sheng, Wei‐Li Chen, Haisong Xie, Hongmei Xu, Xuening Li · 2023 · Frontiers in Pharmacology
  23. Reimagining old drugs with new tricks: Mechanisms, strategies and notable success stories in drug repurposing for neurological diseases
    Neetu Rani, Aastha Kaushik, Shefali Kardam, Sonika Kag, V. Samuel Raj, Rashmi K. Ambasta, Pravir Kumar · 2024 · Progress in molecular biology and translational science
  24. Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity
    Yuqin Ouyang, Xinyue Xiang, Xinyun Hu, Xuehui Chu, Wenjuan Tang, Wenhuan Feng · 2025 · Frontiers in Endocrinology
  25. Targeting the root cause of obesity-related comorbidities through weight independent and dependent actions on insulin sensitivity: Benefits of dual amylin and calcitonin receptor agonists
    Anna Thorsø Larsen, Simone Anna Melander, Khaled Elhady Mohamed, Emilie Ahmt Petersen, Meryem Benmarce, M.A. Karsdal, Kim Henriksen · 2025 · Biomedicine & Pharmacotherapy
  26. Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs
    Maja Cigrovski Berković, Lana Ružić, Vjekoslav Cigrovski, Felice Strollo · 2025 · World Journal of Diabetes
  27. The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome
    Sonal Rajesh Kumar, John E. Anderson, Andrea D. Coviello, F. Lopez-Jimenez, George L. Bakris · 2026 · JACC Advances
  28. Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis
    Gaetano Lauri, Paolo Giorgio Arcidiacono, Antonio Facciorusso, Gabriele Capurso, Matteo Tacelli · 2026 · Pancreatology
  29. Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
    Caterina Conte, Anastassia Amaro · 2026 · Current Diabetes Reports
  30. Pharmacological treatment of obesity
    Gabriela Anglart, Katarzyna Dominiak, Katarzyna Dettlaff · 2023 · Farmacja Polska
  31. Obesity treatment - overview of pharmacological and surgical methods
    Joanna Osiak, Karolina Mikut, Aleksandra Wijata, Kornelia Kędziora–Kornatowska · 2022 · Journal of Education Health and Sport
  32. The effects and side effects of liraglutide as a treatment for obesity
    Jeonghoon Ha, Jin Sok Yu, Joonyub Lee, Hun‐Sung Kim · 2022 · Cardiovascular Prevention and Pharmacotherapy
  33. Combination Therapies
    Megan E White, Vladimir M. Kushnir · 2024 · Gastrointestinal Endoscopy Clinics of North America
  34. Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial
    Wei Fang, Zinan Li, Jie Xu, Jing Zhao, Hongxia Zhu, Huanping Wang · 2026 · Frontiers in Endocrinology
  35. The Glucagon-Like Peptide-1 Analogues therapy in the non-diabetic patients
    Agnieszka Sienicka, Krzysztof Kubasik, Agata Pisula · 2023 · Prospects in Pharmaceutical Sciences
  36. Liraglutide and Exercise: A Possible Treatment for Obesity?
    Ana Paula Azevêdo Macêdo, Renan Fudoli Lins Vieira, Guilherme Domingos Brisque, Gabriela Ferreira Abud, José Rodrigo Pauli · 2022 · Obesities
  37. Review of upcoming and currently available anti-obesity drugs in Europe
    Patryk Gryszkiewicz, Jakub Szydło, Jakub Starownik, Jan Wędrychowski, Bernadeta Anna Zabielska · 2023 · Journal of Education Health and Sport
  38. Pharmacotherapy for weight loss in adults with type 2 diabetes: a systematic review of randomised controlled trials
    Cláudia Matta-Coelho, Rachel Agius, James D. Crane, Barbara M. McGowan · 2021 · British Journal of Diabetes
  39. Obesity and GLP-1 RAs
    Tamis Marie Bright · 2021 · Journal of Investigative Medicine
  40. Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin
    Gavin, Kara L., Amjad, Rabia, Makris, Vaia, Neuner, Joan M. · 2025 · Journal of Managed Care & Specialty Pharmacy
  41. Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis
    Yang Long, Yuxi Zhang · 2023 · Irish Journal of Medical Science (1971 -)
  42. Evaluating Cardio-Protective Molecules by Efficacy Based on Weight Reduction and HbA1c Targets
    Teodor Salmen, Valeria-Anca Pietroșel, Flaviana-Veronica Urzica, Diana-Elena Visan, Bianca-Margareta Salmen, Radu-Cristian Cîmpeanu, Delia Reurean‐Pintilei, Mihaela Simona Popoviciu, Anca Pantea Stoian · 2025 · Biomedicines
  43. Peptidhormonanaloga basierte medikamentöse Adipositastherapie ist effektiv
    Muzamil Hussain, Alexander Dimitri Miras · 2025 · Die Chirurgie
  44. Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression
    Ludovico Abenavoli, Anna Giulia Loricchio, Ivo Lopez, Domenico Morano, Abdulrahman Ismaiel, Dan Lucian Dumitrascu, Francesco Luzza · 2026 · Medicina
  45. Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations
    Iwanger-I-Ter T. Jia, Grace C. Bloomfield, Mike Y. Chen, Marcus H. Cunningham, Annie Wang, Shaun C. Daly, Marcelo W. Hinojosa, Brian R. Smith, Ninh T. Nguyen, Dan Elison Azagury et al. · 2026 · Surgical Endoscopy
  46. Semaglutide versus liraglutide for treatment of obesity
    Nasser E. Mikhail · 2021
  47. Efecto de liraglutide sobre los niveles de andrógenos séricos y la función sexual en mujeres con obesidad
    Franklin José Espitia De La Hoz · 2022 · Revista Colombiana de Endocrinología Diabetes & Metabolismo
  48. Effects of Liraglutide 3.0 mg Injection on Weight Reduction and Metabolic Parameters for Patients Living with Obesity and Type 2 Diabetes Mellitus
    Hanadi Alnageeb, Aseilah Al Qaidy, Ashraf ALakkad, Rania Alsayed Murad, Ibrahim Mahgoub, Masah Mardini, Heba Eyad Shalabi, Ahmad Mhd Asim Rabih, Aji Gopakumar · 2023 · Advances in Research
  49. Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals with Type 2 Diabetes: A Systematic Review
    Huma Irfan, Namratha Pallipamu, Hadi Farhat, Sai Dheeraj Gutlapalli, Suvedha S Thiagaraj, Twisha S Shukla, Sathish Venugopal · 2023 · Cureus
  50. How to apply the Canadian Obesity Clinical Practice Guidelines to people with type 2 diabetes
    Pedersen, Sue D. · 2023 · Canadian Diabetes & Endocrinology Today
  51. Evaluation of the effect of liraglutide therapy on body weight and insulin resistance.
    Dorota Szydlarska, Alicja Jakubowska, Jakub Owoc, Waldemar Wierzba · 2023 · Medycyna Ogólna i Nauki o Zdrowiu
  52. OS IMPACTOS CAUSADOS PELA OBESIDADE NO AUMENTO DOS CASOS MUNDIAIS DE DOENÇAS CARDIOVASCULARES
    Amanda Castro Barroso Pinheiro, Daniela Perri Siqueira, Gabriela de Azevedo Kasper Martins, Ivan Zardo, Jael Andrea Rioja Gamboa, Marcelo Monteiro Mota, Roberta de Melo Coutinho Muniz Oliveira, Thiago Librelon Pimenta · 2024 · EPITAYA eBooks
  53. The Efficacy of Pharmacotherapy in the Treatment of Obesity in Patients With Type 2 Diabetes: A Systematic Review
    Omar Aodah S. Alshahrani, Mohammed S Almalki · 2024 · Cureus
  54. Algoritmo de diagnóstico y tratamiento del sobrepeso y obesidad 2025 de la redGDPS
    Lourdes Carrillo Fernández, Julio Sagredo Pérez, Clara Guede Fernández, Noelia Sanz Vela · 2025 · Diabetes práctica
  55. Adjunctive Therapy, Including Pharmacotherapy
    Dalal Y. Al-Bazz, John P.H. Wilding · 2022 · Wiley eBooks
  56. Reply to the letter to the editor: Lifestyle interventions on weight loss among metabolically healthy obese women
    Magalí Palau‐Rodriguez, Mar Garcia‐Aloy, María Rosa Bernal-López, Ricardo Gómez‐Huelgas, Francisco José Tinahones, Antonio Miñarro, Cristina Andrés‐Lacueva · 2020 · Clinical Nutrition
  57. Recommendations on the Clinical Trial Programme for Diabetes Medicines
    Проскурина Ирина Анатольевна, E. V. Petraneva, Dmitriy Vladimirovich Goryachev · 2021 · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation
  58. Gewichtseffekte der Antidiabetika nutzen
    2020 · Diabetologie und Stoffwechsel
  59. Nutritional Principles in the Treatment of Diabetes
    Roeland J.W. Middelbeek, Samar Hafida, Anna Y. Groysman · 2023 · Nutrition and health
  60. IMPLEMENTAÇÃO FARMACOTERAPÊUTICA DO USO DA LIRAGLUTIDA
    Érika Thaiane Couto Canelas, Jorge Luis dos Santos Farias, Maria Eloneida da Silva Dax, Gisely France Abrantes, Gleicy Kelly China Quemel, Juan Gonzalo Bardález Rivera · 2023 · Revista Ibero-Americana de Humanidades, Ciências e Educação
  61. A eficácia da liraglutida no tratamento da obesidade - uma revisão integrativa
    Isabelle Felix Fonseca, Guilherme Dantas Borges, Gabriel Carneiro Gonçalves, Filipe Portes Moreira, Emílio Conceição de Siqueira · 2023 · Brazilian Journal of Health Review
  62. Effect of Liraglutide on Weight Loss and BMI Among Patients Who Are Overweight and Obese with Type 2 Diabetes: A Systematic Review and Meta-analysis
    C. Zorampari, Rachna Gupta, Lalit K Gupta · 2023 · European Medical Journal
  63. Efikasi Liraglutide Dalam Tatalaksana Obesitas Pada Pasien Dewasa Diabetik dan Non-Diabetik
    Arya Adi Bramasta, Diana Novitasari · 2024 · Malahayati Nursing Journal
  64. GLP-1 RECEPTORIŲ AGONISTŲ REIKŠMĖ 2 TIPO CUKRINIU DIABETU SERGANČIŲ PACIENČIŲ SVORIO MAŽINIMUI
    Miglė Viliušytė, Almantas Maleckas, Mantas Malinauskas · 2024 · Health Sciences
  65. Obesity
    Jacopo Maria Fontana, Paolo Piterà, Federica Verme, Riccardo Cremascoli, Amelia Brunani, Stefania Cattaldo, Stefania Mai, Alessandra Milesi, Laura Bianchi, Federica Galli et al. · 2024 · Springer eBooks
  66. EFICÁCIA E SEGURANÇA DE FÁRMACOS VIA ORAL PARA O MANEJO DO DIABETES MELLITUS TIPO 2
    Konnery Kazelly Marinho, Kelly Rosa Ferreira Ferrari · 2024 · Revista Contemporânea
  67. Effectiveness and Safety of Add-on Once-Daily Liraglutide (1.2 mg) in Type 2 Diabetes Patients with Obesity: Data from a Real-World Cohort of Iraqi Patients
    Haider Ayad Alidrisi, Samih Abed Odhaib, Hussein Ali Nwayyir, Ammar Almomin · 2024 · Clinical Diabetology
  68. Obesity: Interdisciplinary solutions to a multidimensional health problem
    Amanda Bertipaglia Quilis, Daniel Mathias Chagas, Liandra Maria Abaker Bertipaglia, Gabriel Maurício Peruca de Melo · 2024 · Seven Editora eBooks
  69. Metabolic State Determines Central and Peripheral Mechanisms of Liraglutide-Enhanced Insulin Secretion
    Caroline Bonner, Chiara Saponaro, Mónica Imbernón, Isaline Louvet, Eleonora Deligia, Shiqian Chen, Iona Davies, Ana Acosta-Montalvo, Maria Moreno-Lopez, Eve Wemelle et al. · 2024 · Research Square
  70. Real-world evaluation of cardiometabolic outcomes with liraglutide and adjunctive therapies in type 2 diabetes
    Saleem Qureshi, Hamna Ahmed, Mussarat Iqbal, Nighat Batool, Samina Yaseen, Muhammad Daoud Butt · 2025 · Discover Endocrinology and Metabolism
  71. Compare the Decrease in Visceral Adipose Tissue in People with Obesity and Prediabetes vs. Obesity and Type 2 Diabetes Treated with Liraglutide
    Rosa Nayely Hernández-Flandes, María de los Ángeles Tapia-González, Liliana Hernández-Lara, Eduardo Madrigal‐Santillán, Ángel Morales‐González, Liliana Anguiano‐Robledo, José A. Morales‐González · 2025 · Diabetology
  72. Metabolic syndrome: Pharmacological strategies and challenges
    Reza Heidari · 2025 · Elsevier eBooks
  73. What should the doctor prescribe—formula diet or antidiabetics? Effectiveness of formula diet-based lifestyle intervention vs. pharmacological antiglycemic therapy on weight loss and HbA1c reduction in type 2 diabetes patients—a systematic review
    Kerstin Kempf, Martin Röhling, Stéphan Martin · 2025 · Frontiers in Endocrinology
  74. Glucagon-like Peptide-1 Receptor Agonists and Risk of Thyroid Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Dena Osama Khawandanah, Faris F. Alyamani, Bader R. Almutairi, Basil A. Almutairi, Reham Mohammed Alharbi, Shahad Alghanmi, Mohammed T. Alsouri, ABDULAALI R. ALMUTAIRI · 2025 · Saudi Journal of Clinical Pharmacy
  75. Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity
    Yukihiro Wada, Masao Toyoda, Kazuo Kobayashi, Togo Aoyama, Akira Kanamori, Yasuo Takeuchi · 2026 · Clinical and Experimental Nephrology
  76. Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression
    Marella Marassi, Riccardo Maria Pollis, Gian Paolo Fadini · 2026 · Nutrition Metabolism and Cardiovascular Diseases
  77. Low Weight Loss Response to Incretin Analogs: A Systematic Review
    Pamela S. Gaskin, Peter Chami · 2026 · Obesity Reviews
  78. The effect of GLP-1 receptor agonists on osteoarthritis risk in individuals with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized controlled trials
    Limin Zhou, Peiyang Wu, Yongxiang Xu, Baocheng Xie · 2026 · Acta Diabetologica
  79. Impact of Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Therapy and Nutrition Counseling on Body Composition
    Kathryn Hoffman, Peter Gillespie, Candace Smith · 2026 · Journal of Nutrition
  80. COMPREHENSIVE TREATMENT OF TYPE 2 DIABETES IN PATIENTS WITH OBESITY: THE ROLE OF PATIENT EDUCATION, WEIGHT REDUCTION, PHARMACOTHERAPY AND LIFESTYLE MODIFICATION - A NARRATIVE REVIEW
    Magdalena Fąfara, Margartia Jeczkało, Monika Kosiorowska, Agata Kowalczyk, Joanna Lasoń, Marcelina Makulska, Weronika Płachta, Wiktoria Sęk, Amelia Sieradzka, Cezary Michał Wegenko · 2026 · International Journal of Innovative Technologies in Social Science
  81. Identification and functional characterization of a novel mutation in the NEUROD1 gene in a Chinese family with maturity-onset diabetes of the young
    Jianhua Li, Juan Zhang, Shuxin Ren, Yanxia Liu, Cong Wu, J I A N Z E Dong, C F Zhu, Sufang Chen, Huijuan Zhang, T H Li et al. · 2026 · Acta Diabetologica
  82. Obese and overweight patients with type 2 diabetes mellitus are not treated optimally - an overview of current clinical practice and future perspectives
    Tanja Miličević, Ivna Cvitković, Špela Volčanšek, Niki Katsiki, Dimitri P. Mikhailidis, Dimitrios Patoulias, Emir M. Muzurović · 2026 · Expert Review of Clinical Pharmacology
  83. Liraglutide on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review
    Rana R. Alotaibi, Lamya N. Alharbi, Ayah Albash, Ghadah Y. Dumlu, Rawan Alahmadi, Afnan F. Alharbi, Raimaa A Alhassan, Mariam N. Alkarri, Tahani E. Farj, Muath F. Haqwi et al. · 2026 · Journal of Advanced Trends in Medical Research
  84. Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis
    Wiktoria Palka, Paweł Moćko, Katarzyna Śladowska, Przemysław Holko, Paweł Kawalec · 2026 · Journal of Endocrinological Investigation
  85. The clinical relevance of obesity and glucagon-like peptide-1-based therapies for chronic weight management in patients treated by obstetrician-gynecologists and gynecologists: A non-systematic narrative review
    Suzanne Mackey, Celia Egan, Karen E Elkind-Hirsch · 2026 · Therapeutic Advances in Reproductive Health
  86. Diabesity: an old term, a modern challenge — multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes
    Karolina Hoffmann, Weronika Faustyna Pucek, Wiktoria Skrzypek, Filip Kierzkowski, Piotr Ratajczak, Viviana Maggio, Manfredi Rizzo, Mohamed El-Tanani, Syed Arman Rabbani, Bhoomendra A. Bhongade et al. · 2026 · Journal of Pharmacy & Pharmaceutical Sciences